Cover Image
市場調查報告書

心室心搏過速:開發中產品分析

Ventricular Tachycardia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361629
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
心室心搏過速:開發中產品分析 Ventricular Tachycardia - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 42 Pages
簡介

心室心搏過速是發病於心室心搏(跳動)過快的疾病。症狀有頭暈和昏迷、疲勞,胸部疼痛及呼吸急促等。原因有心肌病,缺血性心臟疾病,心臟衰竭等。風險要素有家族病史及病歷。主要治療竹式有使用抗心律不整藥等。

本報告提供全球各國治療心室心搏過速 (心室性心搏過速) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

心室心搏過速;概要

治療藥的開發

  • 心室心搏過速的開發中產品:概要
  • 各企業的開發中產品
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Armetheon Inc
  • Audentes Therapeutics Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International LLC
  • InCarda Therapeutics Inc
  • Milestone Pharmaceuticals Inc
  • 小野藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9303IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2017, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 3 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ventricular Tachycardia - Overview
    • Ventricular Tachycardia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Ventricular Tachycardia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ventricular Tachycardia - Companies Involved in Therapeutics Development
    • Armetheon Inc
    • Audentes Therapeutics Inc
    • Gilead Sciences Inc
    • HUYA Bioscience International LLC
    • InCarda Therapeutics Inc
    • Milestone Pharmaceuticals Inc
    • Ono Pharmaceutical Co Ltd
  • Ventricular Tachycardia - Drug Profiles
    • aladorian sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budiodarone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etripamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flecainide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBI-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landiolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ventricular Tachycardia - Dormant Projects
  • Ventricular Tachycardia - Discontinued Products
  • Ventricular Tachycardia - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
      • Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions
      • Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
      • Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias
      • Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
      • Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
      • Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients
      • Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ventricular Tachycardia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ventricular Tachycardia - Pipeline by Armetheon Inc, H1 2017
  • Ventricular Tachycardia - Pipeline by Audentes Therapeutics Inc, H1 2017
  • Ventricular Tachycardia - Pipeline by Gilead Sciences Inc, H1 2017
  • Ventricular Tachycardia - Pipeline by HUYA Bioscience International LLC, H1 2017
  • Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, H1 2017
  • Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, H1 2017
  • Ventricular Tachycardia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Ventricular Tachycardia - Dormant Projects, H1 2017
  • Ventricular Tachycardia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Ventricular Tachycardia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top